Investigators reported that the classifier could correctly predict cancer type with over 94 percent accuracy and highlighted impacts in a commercially tested cohort.
Using its xT sequencing platform, Tempus will create a companion test to identify patients eligible for treatment with A2's cell-based LOH-targeted therapy.
The firms will use Resolution's ctDx liquid biopsy technology to find non-small cell lung cancer patients who may benefit from Mirati's KRAS G12C inhibitor therapy.
The collaboration builds on an oligonucleotide supply agreement the partners signed in 2019 for Clear Labs' nanopore sequencing-based food safety testing.
Illumina's acquisition of Grail, Exact Sciences' acquisition of Thrive Earlier Detection, and Invitae's acquisition of ArcherDx all topped out at over $1 billion.
The partners are starting by testing patients with colorectal and thyroid cancers using the 648-gene Tempus xT assay, but could expand to other areas in the future.
The firm will scale US-based testing capacity for its LiquidHallmark liquid biopsy assay, which uses amplicon-based technology to detect cancer-related mutations.
The WHO and FIND are supporting NGS-based testing in low-resource settings, while a resistance testing program at New York State's Wadsworth Center has matured.
